Improved Access to PBS medicines for Pulmonary Arterial Hypertension (PAH)

Page last updated: 3 February 2023

Access to PAH PBS medicines has further improved as an outcome of the Post-market Review of PAH medicines. Effective 1 December 2022, PAH patients with World Health Organiation (WHO) Functional Class (FC) III or IV symptoms  have access to endothelin receptor antagonist (ERA) and prostanoid medicines for dual therapy. Patients with WHO FC IV symptoms have access to ERA, prostanoid and phosphodiesterase-5 inhibitor (PDE-5i) medicines for triple therapy. Further information is available in the Plain Language Summary for the PMR of PAH medicines. Refer to the Schedule of Pharmaceutical Benefits, available online, in PDF and in prescribing software, for detailed information on the PBS prescribing restrictions.